论文部分内容阅读
目的探讨熊去氧胆酸(ursodeoxycholic acid,UDCA)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)术后早期胆汁淤滞性肝病的价值。方法选取2003-2007年本院行allo-HSCT术后诊断早期胆汁淤滞性肝病患者26例,序贯入组,分为观察组(12例)和对照组(14例)。观察组应用UDCA口服14mg.kg-1.d-1,治疗14d;对照组S-腺苷蛋氨酸静脉点滴,1g/d,治疗14d。治疗前后分别检测2组患者总胆红素(TB)、直接胆红素(DB)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(GGT)及血清碱性磷酸酶(ALP)的含量,并观察治疗效果。结果观察组显效7例,有效3例,无效2例;对照组显效3例,有效3例,无效8例。结论UDCA治疗allo-HSCT术后早期胆汁淤滞性肝病安全有效,患者耐受良好。
Objective To investigate the clinical value of ursodeoxycholic acid (UDCA) in the treatment of early-stage cholestatic liver disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Totally 26 patients with early-stage cholestatic liver disease who underwent allo-HSCT in our hospital from 2003 to 2007 were selected and divided into observation group (12 cases) and control group (14 cases). The observation group was treated with UDCA orally 14mg.kg-1.d-1 for 14 days. The control group was intravenously administered with S-adenosylmethionine (1g / d) for 14 days. The levels of total bilirubin, direct bilirubin, ALT, AST, GGT and serum alkali The content of alkaline phosphatase (ALP), and observe the therapeutic effect. Results The observation group was markedly effective in 7 cases, effective in 3 cases and ineffective in 2 cases. The control group was markedly effective in 3 cases, effective in 3 cases and ineffective in 8 cases. Conclusions UDCA is safe and effective in the treatment of early-stage cholestatic liver disease after allo-HSCT. The patients are well tolerated.